Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003669 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003669 is a Phase 2 study that has completed, run by Eli Lilly and Company.
The verdict
NCT00003669, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with recurrent, advanced, or metastatic endometrial cancer.
Interventions
- DRUG arzoxifene hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2001-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003669
The ClinicalTrials.gov registry entry for NCT00003669 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arzoxifene hydrochloride is the first listed.
NCT00003669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003669 about?
NCT00003669 is a clinical study titled "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer". RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating w...
What is the current status of trial NCT00003669?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00003669?
The interventions under investigation include: arzoxifene hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003669?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.